国产重组人白细胞介素-11治疗儿童急性非淋巴细胞白血病化疗后血小板减少症的疗效

Therapeutic Effect of Recombinant Human Interleukin-11 on Thrombopenia in Children with Acute Non-Lymphocytic Leukemia after Chemotherapy

目的探讨重组人白细胞介素-11(rhIL-11)对儿童急性非淋巴细胞白血病(急非淋)化疗后血小板减少的防治作用。方法将16例急非淋患儿随机分为治疗组和对照组,其中rhIL-11治疗组于化疗结束后24 h皮下注射rhIL-11[50μg/(kg.d)],连用10～14 d;对照组不用rhIL-11,观察2组血小板减低持续时间、血小板输注量及血小板计数变化及不良反应的发生情况,并进行统计学处理。结果rhIL-11组27例次中有16例次(占59.3%)不需输注血小板即可恢复正常,对照组21例次中仅3例次(占14.3%)不需输注血小板自行恢复,2组比较有显著性差异(P<0.01);rhIL-11组血小板计数下降时间均显著短于对照组;rhIL-11组血小板计数恢复正常的时间也较对照组短,2组比较均有显著性差异(Pa<0.01)。不良反应以乏力、水肿为主,均可缓解。结论rhIL-11可加速急非淋强化治疗后血小板的恢复,预防严重血小板减少症,减少血小板输注,其机制为刺激骨髓巨核细胞生长、分化和成熟。rhIL-11对急非淋强烈化疗后血小板减少有明显的预防和治疗作用,不良反应轻微,与化疗联用可减少出血并发症,使化疗顺利进行。

Objective To explore the preventive and therapeutic effect of recombinant human interleukin-11(rhIL-11) on thrombocytopenia in children with non-lymphocytic leukemia after chemotherapy.Methods Sixteen children who had non-lymphocytic leukemia were divided into 2 groups by randomization,including a therapeutic group and a control group.RhIL-11[50 μg/(kg·d)] was injected subcutaneously 24 h after chemiotherapy in the therapeutic group,and applied consecutively 10-14 days,and the control group was treated with...